Hematopoiesis & Hematologic Malignancies (HHM) Research Program

Theme 2: Hematologic malignancies (HM)

Aim 3

Determine the intrinsic and extrinsic mechanisms used by hematologic malignancies to promote their survival and confer resistance to treatment.

Aim 4

Characterize the immunobiology of hematologic malignancies and utilize this understanding to develop novel therapeutic approaches.

Utpal Davé, MD

Our patients lead us to think harder about these diseases and to generate new ideas.

Utpal Davé, MD — HHM program member

Pediatric blood cancers: Reuben Kapur, PhD

HHM program co-leader Reuben Kapur, PhD, is director of the Herman B Wells Center for Pediatric Research, as well as vice chair for basic science research at IU School of Medicine’s Department of Pediatrics.

Nationally recognized for his work in pediatric blood cancers, Kapur earned two major grants—nearly $4 million in funding—for his research on juvenile myelomonocytic leukemia and acute myeloid leukemia.

His work on obesity-related inflammation and leukemia development was featured in the “Best of Session” at the 63rd American Society of Hematology (ASH) Annual Meeting in December 2021.

Meet Dr. Kapur


Support Our Research